Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Jessica Donington gives a surgeon’s perspective on the treatment of early-stage NSCLC in the era of targeted and immunotherapy options and the importance of helping patients to RIOT.

00:00 Introduction
01:25 Biomarker testing 
03:24 Adjuvant and neoadjuvant immunotherapy
10:10 Unmet needs 
13:35 The current role for surgeons 

Transcript


Meet the faculty

Jessica Donington

Dr Jessica Donington is a Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago. Full biography

Heather Wakelee

Dr Heather Wakelee is a Professor of Medicine and Chief of the Division of Oncology at Stanford University, Deputy Director of the Stanford Cancer Institute, and Interim Medical Director of the Stanford Cancer Center. Full biography

Nasser Altorki

Dr Nasser Altorki is the Vice Chairman of Cardiothoracic Surgery and the Chief of the Division of Thoracic Surgery at the New York-Presbyterian Hospital and is the David B Skinner Professor of Cardiothoracic Surgery at Weill Cornell Medical College. Full biography

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Heather Wakelee and Nasser Altorki discuss the current position on PD-L1 expression and immune checkpoint inhibition in early-stage, resectable NSCLC.

00:00 Introduction 
03:26 PD-L1 testing considerations 
08:47 PD-L1 and the immunotherapy trial findings 
26:08 Dual immunotherapy? 
27:11 Choosing between the options

Transcript


Please feedback


Thank you for watching, please take a moment complete our short survey.

Take the survey
Faculty disclosures

Faculty disclosures

Jessica Donington

Dr Jessica Donington is a speaker for AstraZeneca and has financial relations with the following companies to disclose: Bristol-Myers Squibb and Genetech Inc. All of the relevant financial relationships listed for these individuals have been mitigated.

Heather Wakelee

Heather Wakelee discloses the following relationships and financial interests. She has been an invited speaker, has participated in compensated activities, has received financial support/sponsorship from Companies including: ACEA Biosciences; Arrys Therapeutics; AstraZeneca/Medimmune; BMS; Clovis Oncology; Genentech/Roche; Merck; Novartis; Seagen; Xcovery; Helsinn; Janssen; Daiichi Sankyo; Blueprint; and Mirati.

Nasser Altorki

Nasser Altorki received grants or contracts from AstraZeneca, Janssen, the National Cancer Institute, New York Genome Center P1000, and the US Department of Defense. 

He has received honoraria from AstraZeneca and Regeneron.

Funding and disclaimer

Funding and disclaimer

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited, Springer Nature Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Image Credits

Attention: This content is intended for healthcare professionals only

In order to proceed please confirm whether you are a healthcare professional.

No, I am not a
healthcare professional Yes, I am a
healthcare professional